CIDS CBD Manufacturer in Marmande Enters Judicial Liquidation Amid Regulatory Struggles
CIDS, a Marmande-based CBD manufacturer, enters liquidation due to regulatory challenges impacting its operations.
Key Points
- • CIDS was placed in judicial liquidation on June 5, 2025.
- • The company faced heavy fines and inspections due to evolving Novel Food regulations.
- • Despite a revenue of 1-2 million euros in 2024, CIDS struggled against competition from less regulated European markets.
- • Co-founder Soic Gay Pereira remains optimistic about the future of the French hemp industry.
CIDS, a CBD manufacturing company based in Marmande, has been placed in judicial liquidation as of June 5, 2025, due to ongoing regulatory difficulties within the French market for CBD products. The company has been affected by a challenging regulatory landscape that includes frequent changes to Novel Food regulations, resulting in a series of inspections and fines that hindered its operations.
Established in 2020, CIDS employed approximately ten staff members and reported a revenue of between one and two million euros in 2024, reflecting a steady consumer demand for CBD. However, co-founder Soic Gay Pereira notes that CIDS struggled to compete with less regulated markets in Europe, particularly in Italy and Switzerland, where 80% of CBD flowers consumed in France are imported from due to their more relaxed regulations.
Despite CIDS entering liquidation, Pereira remains hopeful about the future of the French hemp industry and is exploring options to sell CIDS' products to another company, with potential avenues into the cosmetic market. He has expressed a commitment to advancing the French hemp sector and intends to export expertise to the French Caribbean to support development in the area. Pereira's frustration over the evolving regulations underscores the challenges faced by local manufacturers in a climate influenced by broader European competition.